Parameters Correlated to Cardiovascular Disease Risk

An in-depth exploration of key and emerging biomarkers and parameters

---

Highlights

• Comprehensive Biomarker Profiling: Beyond lipid levels, numerous biomarkers such as inflammatory markers, cardiac-specific enzymes, and metabolic parameters contribute to cardiovascular risk assessment.
• Interpretation Criteria Importance: Each parameter comes with its own cutoff values or criteria, emphasizing the need for context-specific evaluation and risk stratification.
• Multi-Parameter and Integrated Approach: Evaluating cardiovascular risk involves combining several markers, clinical history, imaging studies, and lifestyle factors for a more accurate prognosis.

---

Introduction

Cardiovascular diseases (CVD) represent a complex pathology with multiple contributing factors. While the role of low-density lipoprotein (LDL), high-density lipoprotein (HDL), apolipoprotein B (ApoB), and buoyant LDL is well recognized, numerous additional parameters have been associated with, or are strongly suspected to be correlated with, the risk of developing cardiovascular diseases. These parameters span a range of biomarkers, from blood-based enzymatic proteins to inflammatory markers and metabolic parameters, each offering unique insights into the underlying pathological processes such as atherosclerosis, myocardial damage, inflammation, thrombosis, and metabolic imbalance.

Cardiac-Specific Biomarkers

Cardiac-specific biomarkers serve as critical indicators of heart muscle damage and stress, particularly useful in acute settings as well as long-term risk assessment.

Troponins (Troponin T and Troponin I)

Relationship to Cardiovascular Diseases

Troponins are proteins integral to cardiac muscle contraction. When heart muscle is damaged, as seen in myocardial infarction or acute coronary syndrome, troponin levels rise. Elevated values indicate myocardial injury and are essential for diagnosing heart attacks.

Interpretation Criteria

Troponin values are typically interpreted with reference to the 99th percentile of a normal reference population. Levels above this threshold are indicative of cardiac injury. High-sensitivity assays can detect even minor elevations, offering improved early diagnosis.

Creatinine Phosphokinase-MB (CPK-MB)

Relationship to Cardiovascular Diseases

CPK-MB is an isoenzyme predominantly concentrated in heart muscle tissue. While less specific than troponins, its elevated level signifies myocardial damage.

Interpretation Criteria

Elevations in CPK-MB following chest pain are supportive evidence of myocardial infarction. Serial measurements and comparison with troponin rise patterns improve the specificity of diagnosis.

B-Type Natriuretic Peptide (BNP) and NT-proBNP

Relationship to Cardiovascular Diseases

BNP and its amino-terminal fragment NT-proBNP are secreted by the heart in response to ventricular stretching and increased pressure. These markers are highly useful in diagnosing and prognosticating heart failure.

Interpretation Criteria

For BNP, levels below 100 pg/mL are typically seen as normal, while higher values indicate varying degrees of heart failure. NT-proBNP cut-points are age-dependent – usually less than 300 pg/mL for younger individuals, though thresholds adjust for older populations.

ST-2

Relationship to Cardiovascular Diseases

ST-2 is a protein associated with myocardial stress and inflammation. In the context of heart failure, elevated levels can reflect myocardial strain and fibrosis.

Interpretation Criteria

Typically, ST-2 levels that exceed 35 ng/mL are associated with unfavorable outcomes, including a higher risk of mortality in heart failure patients.

---

Inflammatory Markers

Inflammation plays a crucial role in the pathogenesis of atherosclerosis and subsequent cardiovascular events. Several biomarkers are elevated during systemic inflammation and are correlated with heightened cardiovascular risk.

High-Sensitivity C-Reactive Protein (hs-CRP)

Relationship to Cardiovascular Diseases

C-reactive protein is an acute-phase protein produced by the liver. The high-sensitivity version (hs-CRP) can detect minor elevations, signaling low-grade systemic inflammation that is associated with atherosclerotic changes in blood vessels.

Interpretation Criteria

Values below 1.0 mg/L suggest low risk, 1.0-3.0 mg/L indicate moderate risk, and values above 3.0 mg/L reflect high cardiovascular risk.

Fibrinogen

Relationship to Cardiovascular Diseases

Fibrinogen is a glycoprotein involved in blood clot formation. Elevated fibrinogen levels contribute to increased blood viscosity and promote thrombosis, thereby raising the risk for cardiovascular events.

Interpretation Criteria

Normal fibrinogen values are typically in the range of 200-400 mg/dL. Levels exceeding 400 mg/dL are indicative of a higher risk of thrombotic events.

Homocysteine

Relationship to Cardiovascular Diseases

Elevated homocysteine levels are believed to damage the endothelial lining of the arteries, consequently increasing the risk of atherosclerosis and thrombosis.

Interpretation Criteria

Normal homocysteine levels are generally between 5-15 µmol/L. Levels above 15 µmol/L are typically considered high risk.

Growth Differentiation Factor-15 (GDF-15)

Relationship to Cardiovascular Diseases

GDF-15 is a cytokine that exhibits anti-hypertrophic properties but can also serve as a marker for cellular stress. Elevated levels have been correlated with poor outcomes in chronic heart failure and serve as a prognostic marker for all-cause mortality.

Interpretation Criteria

Generally, GDF-15 levels above 1800 pg/mL signal an increased risk of adverse cardiovascular events.

---

Emerging and Advanced Lipid Markers

Aside from traditional lipid profiles, several specialized markers are emerging that provide deeper insights into the composition and behavior of lipid particles, thereby enhancing the prediction of cardiovascular risk.

Lipoprotein(a) [Lp(a)]

Relationship to Cardiovascular Diseases

Lp(a) is a variant of LDL that contains the additional protein apolipoprotein(a). It is genetically determined and plays a crucial role in promoting atherosclerosis and thrombosis, regardless of other lipid parameters.

Interpretation Criteria

Levels below 30 mg/dL are generally associated with lower risk, while values greater than 50 mg/dL denote high cardiovascular risk.

Apolipoprotein A1/Apolipoprotein B Ratio (ApoA1/ApoB Ratio)

Relationship to Cardiovascular Diseases

This ratio offers a balanced assessment of protective high-density lipoproteins (ApoA1) and atherogenic lipoproteins (ApoB). A lower ratio reflects a greater predisposition toward atherosclerotic plaque development.

Interpretation Criteria

A ratio greater than 1.0 is generally considered protective, while a ratio below 1.0 is associated with increased cardiovascular risk.

LDL Particle Size and Number

Relationship to Cardiovascular Diseases

Not all LDL particles are created equal; small, dense LDL particles are more atherogenic than larger ones. Evaluating both the number and size of LDL particles can provide more granular risk assessment.

Interpretation Criteria

While specific cutoffs vary across laboratories, a predominance of small dense LDL particles is correlated with an elevated risk for cardiovascular events.

---

Metabolic Markers

Metabolic parameters provide insights into the broader systemic contributors to cardiovascular risk, especially through their impact on glucose metabolism, insulin sensitivity, and overall energy balance.

Fasting Glucose

Relationship to Cardiovascular Diseases

Elevated glucose levels signal underlying metabolic disturbances, such as diabetes mellitus or insulin resistance, both of which are potent risk factors for coronary artery disease.

Interpretation Criteria

Fasting plasma glucose should be maintained below 100 mg/dL for individuals without diabetes. Values between 100 and 125 mg/dL are classified as prediabetes, and levels above 126 mg/dL typically indicate diabetes.

Hemoglobin A1c (HbA1c)

Relationship to Cardiovascular Diseases

HbA1c provides a long-term average of blood glucose levels over the preceding two to three months. Elevated HbA1c levels have been linked with an increased risk of cardiovascular complications due to chronic hyperglycemia.

Interpretation Criteria

For individuals without diabetes, an HbA1c value below 5.7% is considered normal. Values between 5.7% and 6.4% indicate pre-diabetes, while a value of 6.5% or higher confirms diabetes. For patients with established diabetes, a target HbA1c below 7% is generally advised.

Adiponectin

Relationship to Cardiovascular Diseases

Adiponectin, a hormone produced by adipose tissue, is known for its anti-inflammatory and insulin-sensitizing properties. Lower adiponectin levels have been associated with increased risk of metabolic syndrome and cardiovascular diseases.

Interpretation Criteria

Although normal ranges can vary by assay, lower circulating levels of adiponectin are generally considered to be a risk factor, particularly in the context of obesity and metabolic syndrome.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Relationship to Cardiovascular Diseases

PCSK9 plays a key role in cholesterol metabolism by regulating LDL receptor degradation. Elevated levels contribute to higher LDL cholesterol levels and are a promising therapeutic target in reducing cardiovascular risk.

Interpretation Criteria

Although specific numerical cutoffs for PCSK9 may vary, its activity is inversely related to LDL receptor function; higher circulating levels often correlate with less efficient LDL clearance.

---

Other Relevant Parameters

In addition to the parameters discussed, there are several other novel markers and risk factors that contribute to a broad understanding of cardiovascular risk.

Cystatin C

Relationship to Cardiovascular Diseases

Cystatin C is a marker of renal function that has emerged as a predictor of cardiovascular events. Its elevation may indicate early kidney dysfunction, which is closely linked to cardiovascular morbidity.

Interpretation Criteria

The normal range for cystatin C is typically 0.53-0.95 mg/L. Values above 1.0 mg/L are suggestive of increased cardiovascular risk, especially when accompanied by other risk factors.

Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)

Relationship to Cardiovascular Diseases

Lp-PLA2 is an enzyme bound to LDL particles, and it is involved in the inflammatory process within arterial walls. Elevated levels are associated with the vulnerability of atherosclerotic plaques and an increased risk of stroke and coronary events.

Interpretation Criteria

Levels below 200 ng/mL are generally considered lower risk, whereas values above 200 ng/mL indicate increased inflammatory activity and cardiovascular risk.

Copeptin

Relationship to Cardiovascular Diseases

Copeptin is a surrogate marker for vasopressin, released in response to physiological stress. It has been increasingly recognized as a useful marker in acute settings, particularly in diagnosing myocardial infarction and predicting heart failure outcomes.

Interpretation Criteria

Typically, levels above 14 pmol/L are considered indicative of heightened cardiovascular risk, especially in the context of acute stress responses.

Coronary Artery Calcium (CAC) Score

Relationship to Cardiovascular Diseases

The CAC score measures the extent of calcified plaque in the coronary arteries, serving as a powerful predictor of future cardiovascular events by directly reflecting atherosclerotic burden.

Interpretation Criteria

A score of 0 indicates minimal to no risk, 1-100 suggests low to moderate risk, and scores exceeding 100 are linked to a significantly heightened risk of cardiovascular events.

Ankle-Brachial Pressure Index (ABPI)

Relationship to Cardiovascular Diseases

The ABPI is a non-invasive test used to assess peripheral arterial disease, which is itself an indicator of systemic atherosclerotic burden. A lower ABPI correlates with increased cardiovascular risk.

Interpretation Criteria

Normal ABPI values generally range from 0.9 to 1.3. Values below 0.9 indicate peripheral artery disease and are associated with an elevated risk for cardiovascular events.

C-Terminal pro-Endothelin-1 (CT-proET-1)

Relationship to Cardiovascular Diseases

CT-proET-1 is derived from endothelin-1, a potent vasoconstrictor. Elevated CT-proET-1 levels are indicative of endothelial dysfunction and correlate with increased cardiac mortality.

Interpretation Criteria

Levels above 69.9 pmol/L have been linked to increased cardiovascular risk and adverse outcomes, particularly in settings of advanced vascular disease.

Additional Risk Factors

Beyond the biochemical and imaging markers, several conventional risk factors also play an integral part in comprehensive cardiovascular risk assessment. Although these factors are not blood biomarkers, they are critical in clinical decision-making.

Blood Pressure

Elevated blood pressure directly damages vascular integrity, promoting atherosclerosis and heart failure. Maintaining blood pressure below 120/80 mmHg is key for reducing cardiovascular risk.

Body Mass Index (BMI) and Waist Circumference

Excess body weight, particularly when concentrated around the abdomen, increases the risk of hypertension, diabetes, and heart disease. A BMI between 18.5 and 24.9 and a waist circumference below half of one’s height are indicative of lower cardiovascular risk.

Family History, Age, and Lifestyle Factors

Precise evaluation of cardiovascular risk also involves non-modifiable factors such as family history, age, and ethnicity, as well as modifiable lifestyle factors like smoking, physical activity, diet, and stress management. Each of these elements contributes to the overall risk profile and helps guide preventive and therapeutic strategies.

---

Integrated Risk Assessment

Because of the multifactorial nature of cardiovascular disease, reliance on a single biomarker is usually inadequate. Clinicians are encouraged to use an integrated approach that combines traditional risk factors, novel biomarkers, imaging studies, and clinical judgement. This multi-marker strategy enhances risk stratification by providing a more complete picture of the underlying pathology.

Example of an Integrated Parameter Table

Parameter	Description	Risk Criteria
Troponin T/I	Indicator of myocardial injury	Above 99th percentile of normal
BNP/NT-proBNP	Markers for heart failure	BNP >100 pg/mL; NT-proBNP age-dependent thresholds
hs-CRP	Inflammatory marker	<1 mg/L low risk; >3 mg/L high risk
Lp(a)	Genetically determined lipoprotein	<30 mg/dL low risk; >50 mg/dL high risk
Fibrinogen	Coagulation factor linked to thrombotic risk	200-400 mg/dL normal; >400 mg/dL high risk
Homocysteine	Amino acid impacting endothelial function	5-15 µmol/L normal; >15 µmol/L high risk
CAC Score	Extent of calcified plaque in coronary arteries	0 minimal risk; 1-100 low to moderate risk; >100 high risk

---

Conclusion and Final Thoughts

In summary, the risk of cardiovascular diseases is intricately linked to a wide spectrum of biomarkers and parameters. Beyond the well-known parameters such as LDL, HDL, ApoB, and buoyant LDL, both familiar and emerging markers contribute vital diagnostic and prognostic information. Cardiac-specific markers, including troponins, CPK-MB, and natriuretic peptides, are pivotal for identifying myocardial injury and heart failure. Inflammatory markers like hs-CRP, fibrinogen, and homocysteine underscore the role of systemic inflammation in the development of atherosclerosis.

Emerging markers, including Lp(a), the ApoA1/ApoB ratio, and LDL particle size, offer enhanced insights into lipid subfraction risk, thereby complementing traditional lipid profiles. Metabolic markers such as fasting glucose, HbA1c, adiponectin, and PCSK9 contribute significantly by revealing underlying metabolic dysfunction and its cardiovascular implications.

Additionally, parameters like cystatin C, Lp-PLA2, copeptin, CT-proET-1, and the coronary artery calcium score provide valuable information on organ-specific stress and injury, systemic inflammation, and atherosclerotic burden. Along with these quantitative biomarkers, traditional risk factors such as blood pressure, body mass index, family history, and lifestyle choices remain indispensable in the comprehensive evaluation of cardiovascular risk.

The multi-marker approach not only enriches clinical assessment but also enables tailored therapeutic strategies designed to mitigate risk factors effectively. As cardiovascular research progresses, the integration of these markers into routine clinical practice will likely refine risk prediction models and ultimately lead to improved patient outcomes.

---

References

• Classical and Novel Biomarkers for Cardiovascular Risk Prediction - PubMed Central
• Emerging biomarkers for the detection of cardiovascular diseases - PubMed Central
• Emerging biomarkers for the detection of cardiovascular diseases - The Egyptian Heart Journal
• Biomarkers in Cardiovascular Disease - PubMed Central
• Novel biomarkers for cardiovascular risk prediction - PubMed Central
• Circulating Biomarkers for Cardiovascular Disease Risk Prediction - Frontiers in Cardiovascular Medicine
• Multifaceted role of cardiovascular biomarkers - ScienceDirect
• Cardiac Enzymes (Biomarkers): Types & What They Do - Cleveland Clinic
• 2025 Predictions About Cardiovascular - Mass General Brigham

---

Recommended Further Queries